PharmaJet touted its needle-free injection technology in a study that evaluated the use of its device in company-hosted flu clinics.
The report, which was published in ONdrugDelivery, described the experience that patients and healthcare providers had with its Stratis needle-free injection system in influenza clinics hosted by companies including BP Oil, Cargill, Xerox and the Denver International Airport.
PharmaJet’s device is designed to administer medication intramuscularly or subcutaneously, without the use of needles. The company describes the technology as a way to prevent cross-contamination between needles and enhance patient compliance.
Only 20% of healthy, working adults ages 18 – 49 receive an annual flu shot, despite the benefits of vaccination, according to PharmaJet.
The Golden, Colo.-based company reported that over 90% of patients and healthcare providers were satisfied with the needle-free shot and that 33% of healthcare providers thought that having a needle-free option would increase vaccination rates in their workplace programs.
PharmaJet also found that 95% of patients would choose to receive their flu shot with a needle-free injection during next year’s flu vaccination season.
“Our experience last flu season is consistent with previous patient and provider surveys. Offering our needle-free technology as an option in workplace flu clinics can be beneficial to employee health while improving organization productivity,” chairman & CEO Ron Lowy said in prepared remarks. “We look forward to expanding the availability of needle-free in workplace immunization clinics this fall.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news